0000000000622547
AUTHOR
A. Chiara
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET
Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. In addition, when surgery/invasive procedures are needed while on emicizumab, their management requires multidisciplinary competences and direct supervision by experts in the use of this agen…
Electronic modifications in (Ba,La)(Fe,Zn,Y)O3−δ unveiled by oxygen K-edge X-ray Raman scattering
Oxides with mixed protonic-electronic conductivity are relevant as oxygen electrodes for protonic ceramic fuel cells and electrolyzers. We investigate the modification of the electronic structure of (Ba,La)(Fe,Zn,Y)O3−δ when iron is partially replaced by Zn2+ or Y3+ and when it changes between 3+ and 4+ formal oxidation states. With a combination of X-ray Raman scattering (O K-edge) and X-ray absorption near edge structure (Fe, Zn, and Y K-edges) and the corresponding simulations reproducing the spectroscopic data, we quantitatively analyze the degree of covalency of the Fe-O bonds in reduced (Fe mainly 3+) and oxidized (Fe mainly 4+) materials. The simulations employ two semi-empirical par…